You · The journal of prevention of Alzheimer's disease 2026 · retrospective clinicopathological cohort study · n=?

The concurrent burden of Alzheimer's pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline.

Cited 0 times in the scientific literature.

Level 3 - non-randomized controlled study

Retrospective clinicopathological cohort study using autopsy database records.

PubMed 41996885 · doi:10.1016/j.tjpad.2026.100568 · record verified 2026-08-26

What was done

Researchers conducted a retrospective clinicopathological study using the National Alzheimer's Coordinating Center (NACC) database of autopsy-confirmed participants aged 50 and older. Structural equation modeling (SEM) was used to assess mediation pathways linking Alzheimer's disease pathology (Thal phase) to cerebral amyloid angiopathy (CAA) severity, cortical microinfarcts, and cognitive performance measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB). The modifying effect of APOE genotype was assessed, and cognitive impairment was compared between individuals with pure Alzheimer's disease pathology and those with a "Triple Hit" of Alzheimer's pathology, CAA, and microvascular injury.

What was found

SEM identified a statistically significant pathway where parenchymal amyloid was associated with CAA, which in turn correlated with higher risk of microinfarcts and subsequent cognitive dysfunction. APOE ε4 carriers experienced a steeper trajectory of cognitive decline for a given severity of CAA compared to non-carriers. Patients with the "Triple Hit" demonstrated significantly worse cognitive impairment than those with pure Alzheimer's disease pathology (P < 0.001), adjusting for age and education. Numerical effect sizes, sample counts, and regression coefficients were not reported in the abstract.

Why it matters

The findings indicate that vascular co-pathology is an active mediator of cognitive failure rather than an incidental bystander in Alzheimer's disease, particularly among APOE ε4 carriers. This supports targeting vascular resilience and cerebrovascular mechanisms alongside anti-amyloid strategies.

Limits

The abstract does not state the sample size or demographic details. The analysis relies on retrospective post-mortem autopsy data from the NACC database, which is subject to referral and selection biases. Because pathology was evaluated at autopsy, temporal ordering of lesion development relative to longitudinal clinical stages is inferred rather than directly observed. Specific effect estimates and confidence intervals are omitted from the abstract.

Cited by